Kidney disease and hemodialysis: identification of blood biomarkers to detect heart failure and kidney failure

Abstract

Objectives: to identify valid blood biomarkers to detect heart failure and kidney failure associated with kidney disease and hemodialysis.
 Methods: systematic literature review conducted in August 2018 in the following: Web Of Science, PubMed, Scopus, Cinahal, Cochrane, Science Direct and Lilacs. The guiding question was: “What are the blood biomarkers used to detect heart failure and kidney failure?” A total of 537 publications were found, 94 of these appeared more than once, 383 were excluded after reading titles and abstracts, 32 were excluded after reading the full texts, and 10 were excluded in the quantitative and qualitative synthesis. 
 Results: 18 papers compose the final sample and report laboratory and imaging tests, instruments to assess the risk of kidney and heart failure, and also clinical management of the progression of kidney and heart failure. All the studies correlated risk of mortality and mortality.
 Conclusion: laboratory tests are important to identifying kidney and heart failure and need to be used to improve clinical management of the hemodialysis treatment of people with chronic kidney disease in order to improve quality of life and life expectancy.

Effect of hyperbaric oxygen (HBO) therapy on kidney function in metabolic syndrome (MetS) patients

“…The mortality rate for patients with chronic kidney disease (CKD) who underwent hemodialysis ranged from 0.4 to 10.04 deaths per 100 people every year (Ramesh et al, 2016). The main type of mortality is sudden cardiac death, while it is stated 13 deaths occur to per 100 people every year (Mayer et al, 2020).…”